Literature DB >> 16437689

Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome.

S D Mansfield1, O Barakat, R M Charnley, B C Jaques, C B O'Suilleabhain, P J Atherton, D Manas.   

Abstract

AIM: To assess the management and outcome of hilar cholangiocarcinoma (Klatskin tumor) in a single tertiary referral center.
METHODS: The notes of all patients with a diagnosis of hilar cholangiocarcinoma referred to our unit for over an 8-year period were identified and retrospectively reviewed. Presentation, management and outcome were assessed.
RESULTS: Seventy-five patients were identified. The median age was 64 years (range 34-84 years). Male to female ratio was 1:1. Eighty-nine percent of patients presented with jaundice. Most patients referred were under Bismuth classification 3a, 3b or 4. Seventy patients required biliary drainage, 65 patients required 152 percutaneous drainage procedures, and 25 had other complications. Forty-one patients had 51 endoscopic drainage procedures performed (15 failed). Of these, 36 subsequently required percutaneous drainage. The median number of drainage procedures for all patients was three, 18 patients underwent resection (24%), nine had major complications and three died post-operatively. The 5-year survival rate was 4.2% for all patients, 21% for resected patients and 0% for those who did not undergo resection (P = 0.0021). The median number of admissions after diagnosis in resected patients was two and three in non-resected patients (P<0.05). Twelve patients had external-beam radiotherapy, seven brachytherapy, and eight chemotherapy. There was no significant benefit in terms of survival (P = 0.46) or hospital admissions.
CONCLUSION: Resection increases survival but carries the risk of significant morbidity and mortality. Percutaneous biliary drainage is almost always necessary and endoscopic drainage should be avoided if possible.

Entities:  

Mesh:

Year:  2005        PMID: 16437689      PMCID: PMC4723393          DOI: 10.3748/wjg.v11.i48.7625

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach.

Authors:  K D Lillemoe; J L Cameron
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

Review 2.  Hilar cholangiocarcinoma: a review and commentary.

Authors:  R S Chamberlain; L H Blumgart
Journal:  Ann Surg Oncol       Date:  2000 Jan-Feb       Impact factor: 5.344

3.  Long-term outcome in patients with advanced hilar bile duct tumors undergoing palliative endoscopic or percutaneous drainage.

Authors:  P Born; T Rösch; K Brühl; W Sandschin; N Weigert; R Ott; E Frimberger; H D Allescher; W Hoffmann; H Neuhaus; M Classen
Journal:  Z Gastroenterol       Date:  2000-06       Impact factor: 2.000

4.  Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma.

Authors:  H Shinchi; S Takao; H Nishida; T Aikou
Journal:  J Surg Oncol       Date:  2000-10       Impact factor: 3.454

5.  Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents.

Authors:  J Lammer; K A Hausegger; F Flückiger; F W Winkelbauer; R Wildling; G E Klein; S A Thurnher; L Havelec
Journal:  Radiology       Date:  1996-10       Impact factor: 11.105

6.  Pathological aspects of cholangiocarcinoma.

Authors:  K Weinbren; S S Mutum
Journal:  J Pathol       Date:  1983-02       Impact factor: 7.996

7.  Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer.

Authors:  G Falkson; J M MacIntyre; C G Moertel
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

8.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

Review 9.  Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.

Authors:  E C Burke; W R Jarnagin; S N Hochwald; P W Pisters; Y Fong; L H Blumgart
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

Review 10.  Indications for liver transplantation in hepatobiliary malignancy.

Authors:  R Pichlmayr; A Weimann; B Ringe
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

View more
  21 in total

1.  Preoperative evaluation with T-staging system for hilar cholangiocarcinoma.

Authors:  Ru-Fu Chen; Zhi-Hua Li; Jia-Jia Zhou; Jie Wang; Ji-Sheng Chen; Qing Lin; Qi-Bing Tang; Ning-Fu Peng; Zhi-Peng Jiang; Quan-Bo Zhou
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

2.  Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma.

Authors:  Zheng Shi; Ming-Zhi Yang; Qing-Liang He; Rong-Wen Ou; You-Ting Chen
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

3.  Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Mario Fernández-Ruiz; Juan-Manuel Guerra-Vales; Francisco Colina-Ruizdelgado
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

4.  Acute onset of generalised pruritus as presenting symptom of Klatskin tumour.

Authors:  Patrick Tobbia; Leslie A Norris; Nodira Karimova
Journal:  BMJ Case Rep       Date:  2012-08-08

Review 5.  The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade?

Authors:  Neil Bhardwaj; Giuseppe Garcea; Ashley R Dennison; Guy J Maddern
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

6.  Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma.

Authors:  Xiao-Fang Liu; Hao Zhang; Shi-Guang Zhu; Xian-Ting Zhou; Hai-Long Su; Zheng Xu; Shao-Jun Li
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

7.  Slug inhibition upregulates radiation-induced PUMA activity leading to apoptosis in cholangiocarcinomas.

Authors:  Kejun Zhang; Bingyuan Zhang; Yun Lu; Chuandong Sun; Wei Zhao; Xuelong Jiao; Jilin Hu; Peng Mu; Hai Lu; Changyong Zhou
Journal:  Med Oncol       Date:  2010-12-01       Impact factor: 3.064

8.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

9.  TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma.

Authors:  Shanglei Ning; Sen Guo; Jianjun Xie; Yunfei Xu; Xiaofei Lu; Yuxin Chen
Journal:  J Gastrointest Surg       Date:  2012-12-01       Impact factor: 3.452

10.  Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant.

Authors:  Jimme K Wiggers; Bas Groot Koerkamp; Kasia P Cieslak; Alexandre Doussot; David van Klaveren; Peter J Allen; Marc G Besselink; Olivier R Busch; Michael I D'Angelica; Ronald P DeMatteo; Dirk J Gouma; T Peter Kingham; Thomas M van Gulik; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2016-04-05       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.